National and Kapodistrian University of Athens
Προσδιορισμός και μελέτη των μετα-μεταγραφικών τροποποιήσεων Ν6-μεθυλαδενοσίνη και 5-μεθυλοκυτοσίνη των ανθρώπινων mRNAs στον καρκίνο του μαστού
Abstract
dc:descriptionThe study of post-transcriptional RNA modifications constitutes a rapidly expanding frontier in molecular biology, unveiling additional layers of gene expression and regulation beyond DNA sequence and epigenetic mechanisms. Among more than 170 different modifications that have been described, N6-methyladenosine (m6A) and 5-methylcytosine (m5C) stand out as the most abundant and well-studied. These modifications play a central role in mRNA metabolism by influencing transcript stability, modulating translational efficiency, and controlling degradation rates, thereby shaping cellular functions and contributing to disease phenotypes. Three distinct groups of enzymes have been identified in the regulation of RNA modifications: writers, which catalyze the deposition of modifications; erasers, which remove them; and readers, which recognize and interpret them. The functional characterization of these enzyme classes, together with insights into the biological roles of the modifications themselves, has firmly established the epitranscriptome as a dynamic and reversible layer of gene expression regulation that can rapidly adapt to cellular signals and pathways. The detection of RNA modifications has traditionally relied on antibody-based immunoprecipitation approaches, including m6A-seq, MeRIP-seq, and miCLIP, which enabled transcriptome-wide mapping of methylated regions but suffer from limited nucleotide resolution, antibody cross-reactivity, and difficulties in accurately quantifying methylation stoichiometry. On the contrary, chemical-based methods, such as RNA bisulfite sequencing (RBS-seq), provided single-nucleotide resolution maps of 5-methylcytosine (m5C) but were hampered by partial RNA degradation, incomplete conversion, and limited specificity in distinguishing closely related modifications. Additional techniques, including Aza-IP, PA-m6A-seq, and MazF-based cleavage assays, have been employed to improve detection sensitivity and resolution, yet these approaches remain labor-intensive and prone to technical artifacts. In recent years, the advent of third-generation sequencing, particularly direct RNA sequencing using nanopores (Oxford Nanopore Technologies, ONT), has revolutionized the field. This platform directly records the ionic current disruptions generated as modified nucleotides pass through the nanopore, thereby capturing the intrinsic ‘electrical signatures’ of modifications without the need for chemical treatment, reverse transcription, or amplification. Such an approach enables the simultaneous acquisition of both primary sequence and epitranscriptomic information at single-molecule resolution, facilitating the identification of RNA modifications and their dynamic distribution across diverse transcriptomes. Notably, these advances have transformed epitranscriptomic profiling from indirect, antibody- and chemical-assisted methods into a direct, high-resolution, and quantitative framework for studying the functional role of RNA modifications. Breast cancer is the most frequently diagnosed malignancy in women worldwide and represents a major cause of cancer-related mortality. A hallmark of the disease is its pronounced heterogeneity at both molecular and clinical levels, which is reflected in the classification of distinct subtypes, including luminal A, luminal B, HER2-positive, and triple-negative breast cancer (TNBC). These subtypes differ markedly in their molecular signatures, clinical progression, and therapeutic responses. Emerging evidence indicates that RNA modifications—particularly N6-methyladenosine (m6A) and 5-methylcytosine (m5C)—play pivotal roles in breast cancer biology by influencing key processes such as cell proliferation, invasion, metastasis, and resistance to therapy. While the enzymatic machinery responsible for installing, removing, and interpreting these modifications has been extensively studied, the precise transcriptome-wide distribution, dynamics, and functional consequences of m6A and m5C in human breast cancer remain insufficiently characterized. A deeper understanding of these RNA modifications in the context of breast cancer holds promise for identifying novel biomarkers, uncovering mechanisms underlying disease heterogeneity, and developing innovative therapeutic strategies tailored to specific molecular subtypes.In the present thesis, a comprehensive and systematic study of m6A and m5C modifications in breast cancer cell lines was conducted, leveraging nanopore sequencing technology combined with bioinformatics analysis. Five breast cancer cell lines representing major molecular subtypes (MCF-7, BT-474, BT-20, MDA-MB-231, and SK-BR-3), as well as the non-cancerous MCF-10A cell line as a normal control, were used. Bioinformatics analysis revealed thousands of potential m6A and m5C sites, of which approximately 1–2% were classified as “high-confidence” sites based on stringent criteria, minimizing false positives. A strong preference of m6A for the conserved 5'-DRACH-3' motif, which is recognized by the METTL3/14 methyltransferase complex, was confirmed, while m5C was found in more complex motifs, with a notable enrichment at the 5'-CNGGG-3' motif, characteristic of NSUN2. Both modifications appeared across all mRNA regions, with a preference for 3' UTRs, particularly near stop codons. Differential methylation analysis between cancerous and non-cancerous cells revealed primarily increased methylation levels in the cancerous cell lines. Comparative analysis among breast cancer molecular subtypes revealed both shared and subtype-specific methylation sites, reflecting the molecular heterogeneity of the disease. In addition, the role of two key enzymes, the demethylase ALKBH5 and the methyltransferase NSUN2, were investigated through gene editing using the CRISPR/Cas9 system. This intervention led to significant changes in the corresponding modification levels, confirming their crucial role in the regulation of the epitranscriptome. Specifically, the loss of ALKBH5 was associated with increased m6A levels at certain 5'-DRACH-3' motifs, suggesting selectivity in its activity and potential involvement of additional enzymes in m6A removal. Similarly, knockout of the NSUN2 gene led to reduced m5C levels at its target motifs, while the detection of novel methylation sites in previously uncharacterized regions supports the idea that other methyltransferases may also regulate m5C modifications in human mRNAs. One of the most significant achievements of the present doctoral dissertation was the design, construction, and functional evaluation of an innovative molecular tool that combines the catalytically inactive form of the RfxCas13d protein (dRfxCas13d) with the human RNA demethylase ALKBH5, enabling the targeted demethylation of specific m6A sites in human mRNAs. The plasmid vector Dem6A-Vec, developed in the context of this study, incorporates all the necessary components for the co-expression of the dRfxCas13d–ALKBH5 complex and the corresponding gRNA, providing a unified, “all-in-one” system with high efficiency and specificity. The implementation of the system in human cells demonstrated its ability to induce precise and selective demethylation at specific m6A sites without off-target effects. Experimental results confirmed that the removal of m6A from selected mRNAs can affect their stability and, consequently, modulate gene expression with high accuracy and specificity. Furthermore, analysis of methylation dynamics revealed that the demethylation achieved by the system is transient and reversible, reflecting the inherent plasticity of the epitranscriptome. This transience depends on the half-life of the mRNAs, the synthesis of new transcripts, and the presence and expression of the plasmid within the cells. The ability to achieve targeted, non-permanent, and tunable modulation of m6A methylation levels at single-nucleotide resolution provides a powerful framework for investigating the functional consequences of post-transcriptional modifications. Overall, the in-house developed Dem6A-Vec system constitutes a robust, scalable and versatile tool for precise RNA editing and the functional dissection of individual m6A sites, providing novel insights into the plasticity and reversibility of RNA modifications, and offering a powerful methodological advance with direct implications for cancer biology and the development of future therapeutic strategies. In summary, the present thesis demonstrates that the implementation of third-generation sequencing technology, advanced bioinformatics analysis, and innovative molecular approaches—such as the in-house developed targeted m6A demethylation system—provides a reliable and comprehensive mapping of m6A and m5C modifications in breast cancer. Ultimately, the present doctoral thesis not only contributes new knowledge on breast cancer pathogenesis and heterogeneity but also paves the way for exploiting epitranscriptomic modifications as potential biomarkers and/or therapeutic targets in the context of personalized medicine.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2025
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Athanasopoulou, Konstantina
- Αθανασοπούλου, Κωνσταντίνα
Subjects
dc:subject × 18- Μετα-μεταγραφικές Τροποποιήσεις
- 6-μεθυλαδενοσίνη
- 5-μεθυλο-κυτοσίνη
- Γονιδιακή αποσιώπηση
- Αλληλούχηση νανοπόρου
- Επιμεταγραφωμική
- RNA modifications
- Nanopore sequencing
- CRISPR/Cas9 based genome wide screen
- CRISPR/Cas13
- SELECT qPCR
- RNA editing
- Βιολογία
- Φυσικές Επιστήμες
- Βιοχημεία και Μοριακή βιολογία
- Biological Sciences
- Natural Sciences
- Biochemistry and Molecular Biology
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/60565